Yissum - Research Development Company of the Hebrew University

New CB2 agonists (HU910)

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

New CB2 agonists (HU910)
Project ID : 9-2008-2188

Description of the technology

Wide range of disorders including inflammation, pain, neurological and neurodegenerative diseases, MS, cancer

Categories

Immunology, Inflammation, CNS, Cardiovascular, Small Molecule

Development Stage

Tested in head injury small animal model

Patent Status

Provisional Patent filed in the United States

Market

Wide range of disorders representing enormous market opportunity; multiple sclerosis market will reach upwards of $20 billion in 2012

Highlights

  • Agonists that bind well to the cannabinoid CB2 receptor and do not bind, or only bind weakly to the cannabinoid CB1 receptor are very promising therapeutic compounds for a wide range of disorders.
  • CB1 agonists (such as the marijuana constituent THC) lead to undesirable side psychoactive effects. Therefore CB1 agonists, which act on the central nervous system, are of limited therapeutic value
  • These compounds bind specifically to the cannabinoid CB2 receptor
  • Demonstrated improvement in head injury in small animals – reduces production of PNF alpha

Our Innovation

Novel small molecule compounds that are agonists specifically to the cannabinoid CB2 receptor for the treatment of diseases associated with stimulation of CB2 receptors

Key Features

Low-cost, specific compounds for treating a wide variety of disorders without producing side effects

Development Milestones

Seeking funding for ongoing research; licensing agreements with companies in the fields mentioned below to develop specific therapeutic compounds

The Opportunity

Compounds have applications in wide range of disorders including: inflammation; pain; neurological and neurodegenerative diseases; liver diseases; cerebral injury; cancer; retinal vascularisation; endometritis; atherosclerosis, disorders related to anti-fibrinogenic effects; inflammatory bowel disease; arthritis; and in stimulation of bone growth, bone repair or prevention of bone loss in osteoporosis and bone fracture.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Raphael Mechoulam
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Itai Bab
HUJI, Faculty of Dental Medicine

Esther Shohami
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Lital Magid
HUJI, School of Medicine - IMRIC

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Diagnostic
  • Therapeutic
  • Other Medical/Health Related
  • Agro and Marine biotech
  • Anatomy, Pathology, Immunology, Physiology
  • Clinical Medicine
  • cns
  • Life Science & Biotechnology

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.